Close Menu

Beckman Coulter

The test measures IgG antibodies directed to the spike protein of the virus and has demonstrated 99.9 percent specificity and 98.9 percent sensitivity.

Under the agreement, Beckman Coulter will sell and distribute Genedrive's high-throughput SARS-CoV-2 test in the US and Europe.

The company's life sciences revenues grew 76 percent, while diagnostics revenues increased 24 percent.

The BioFire Defense subsidiary of BioMérieux obtained clearance for its FilmArray Global Fever Panel External Control Kit, used with the FilmArray Global Fever Panel.

Emerging technologies included biosensors, host response tests using different types of biomarkers, and new ways to make and develop antigen, antibody, and PCR tests.

The IgM test had nearly 100 percent specificity with 1,400 negative samples and 98 percent sensitivity with samples 15 to 30 days after symptom onset.

The test uses the sTRA biomarker to differentiate between different subtypes of pancreatic cancer, including those that are resistant to chemotherapy.

The ratio of IL-6 to IL-10 biomarkers might give clinicians insight into how severe the inflammatory response to SARS-CoV-2 could be in certain patients.

The revenue increase was driven by significant growth in the conglomerate's life sciences segment.

The firm was awarded the funding to validate its monocyte distribution width hematology biomarker for the detection of multisystem inflammatory syndrome in children.